DK3132791T3 - Hæmning af metastaser med forbindelser, som reducerer den vedvarende del af den spændingsafhængige natriumkanal - Google Patents

Hæmning af metastaser med forbindelser, som reducerer den vedvarende del af den spændingsafhængige natriumkanal Download PDF

Info

Publication number
DK3132791T3
DK3132791T3 DK16020321.2T DK16020321T DK3132791T3 DK 3132791 T3 DK3132791 T3 DK 3132791T3 DK 16020321 T DK16020321 T DK 16020321T DK 3132791 T3 DK3132791 T3 DK 3132791T3
Authority
DK
Denmark
Prior art keywords
metastases
inhibition
compounds
voltage
reduce
Prior art date
Application number
DK16020321.2T
Other languages
English (en)
Inventor
Mustafa Bilgin Ali Djamgoz
Original Assignee
Celex Oncology Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celex Oncology Innovations Ltd filed Critical Celex Oncology Innovations Ltd
Application granted granted Critical
Publication of DK3132791T3 publication Critical patent/DK3132791T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16020321.2T 2010-10-13 2010-10-13 Hæmning af metastaser med forbindelser, som reducerer den vedvarende del af den spændingsafhængige natriumkanal DK3132791T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16020321.2A EP3132791B1 (en) 2010-10-13 2010-10-13 Inhibition of metastasis by compounds which reduce the persistent part of the voltage-gated sodium channel
EP10776791.5A EP2627321A1 (en) 2010-10-13 2010-10-13 Treatment of cancer/inhibition of metastasis
PCT/GB2010/001908 WO2012049440A1 (en) 2010-10-13 2010-10-13 Treatment of cancer/inhibition of metastasis

Publications (1)

Publication Number Publication Date
DK3132791T3 true DK3132791T3 (da) 2020-03-09

Family

ID=44022817

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16020321.2T DK3132791T3 (da) 2010-10-13 2010-10-13 Hæmning af metastaser med forbindelser, som reducerer den vedvarende del af den spændingsafhængige natriumkanal

Country Status (13)

Country Link
US (5) US20130203764A1 (da)
EP (3) EP3132791B1 (da)
JP (1) JP2013539778A (da)
KR (1) KR20140032346A (da)
CN (2) CN112755029A (da)
AU (2) AU2010362412A1 (da)
BR (1) BR112013009086A2 (da)
CA (1) CA2851694C (da)
DK (1) DK3132791T3 (da)
IL (1) IL225689A0 (da)
RU (1) RU2013121744A (da)
SG (1) SG189352A1 (da)
WO (1) WO2012049440A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3132791B1 (en) 2010-10-13 2019-11-27 Celex Oncology Innovations Limited Inhibition of metastasis by compounds which reduce the persistent part of the voltage-gated sodium channel
WO2013123403A1 (en) * 2012-02-15 2013-08-22 Sanford-Burnham Medical Research Institute Theranostics platform and methods of use
WO2017091574A1 (en) * 2015-11-25 2017-06-01 Health Research, Inc. Riluzole and riluzole drug combinations for the treatment of prostate cancer
JP6465306B2 (ja) * 2016-02-04 2019-02-06 セレックス・オンコロジー・リミテッド 癌の治療/転移の阻害
CN110662545A (zh) * 2017-02-10 2020-01-07 赛立斯肿瘤学创新有限公司 癌症治疗和转移抑制
US20200123544A1 (en) * 2018-10-22 2020-04-23 Celex Oncology Innovations Limited Gene therapy targeting the neonatal form of nav1.5 for treating cancer
KR20220087509A (ko) 2019-10-24 2022-06-24 셀렉스 온콜로지 이노베이션즈 리미티드 암의 조합 치료
EP4093769A1 (en) 2020-01-21 2022-11-30 Celex Oncology Innovations Limited Monoclonal antibodies against neonatal nav1.5
US20230139204A1 (en) 2020-03-09 2023-05-04 Celex Oncology Innovations Limited Measuring electric activity of cells for the evaluation of metastatic potential of cancer cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1659136A (zh) * 2002-04-18 2005-08-24 弗吉尼亚大学专利基金会 新的钠通道阻滞剂
US6979675B2 (en) * 2003-01-10 2005-12-27 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
US8835473B2 (en) * 2004-04-16 2014-09-16 Rutgers, The State University Of New Jersey Methods and compositions for treating cancer
WO2009105230A2 (en) * 2008-02-21 2009-08-27 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
US20110251144A1 (en) * 2008-09-16 2011-10-13 Massachusetts Institute Of Technology Molecular modulators of the wnt/beta-catenin pathway
EP3132791B1 (en) 2010-10-13 2019-11-27 Celex Oncology Innovations Limited Inhibition of metastasis by compounds which reduce the persistent part of the voltage-gated sodium channel

Also Published As

Publication number Publication date
CN103370060A (zh) 2013-10-23
KR20140032346A (ko) 2014-03-14
JP2013539778A (ja) 2013-10-28
US20200017457A1 (en) 2020-01-16
AU2017202267B2 (en) 2019-01-24
EP3132791B1 (en) 2019-11-27
US11634398B2 (en) 2023-04-25
WO2012049440A1 (en) 2012-04-19
US20180346431A1 (en) 2018-12-06
CA2851694A1 (en) 2012-04-19
CN112755029A (zh) 2021-05-07
AU2010362412A1 (en) 2013-05-30
US20230202994A1 (en) 2023-06-29
BR112013009086A2 (pt) 2016-07-26
CA2851694C (en) 2019-02-26
SG189352A1 (en) 2013-05-31
US20160096812A1 (en) 2016-04-07
RU2013121744A (ru) 2014-11-20
IL225689A0 (en) 2013-06-27
EP2627321A1 (en) 2013-08-21
AU2017202267A1 (en) 2017-04-27
EP3653206A1 (en) 2020-05-20
EP3132791A1 (en) 2017-02-22
US20130203764A1 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
DK3132791T3 (da) Hæmning af metastaser med forbindelser, som reducerer den vedvarende del af den spændingsafhængige natriumkanal
DK3239134T3 (da) Pyridonamider som modulatorer af natriumkanaler
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
DK3466949T3 (da) Tricyklisk forbindelse som anticancermidler
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
DK2954051T3 (da) Modificeret kapsid til genoverførsel til behandling af nethinden
CR20140259A (es) Compuestos novedosos de benzopirano, composiciones y usos de los mismos
DK2693881T3 (da) Substituerede n-phenylpyrimidin-2-amin-analoger som inhibitorer af axl-kinase
EP2681200A4 (en) INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
DK3181567T3 (da) Pyrazolopyrimidinforbindelser som kinasehæmmere
DK3590928T3 (da) Pyrimidinderivater til behandling af virusinfektioner
DK2315756T3 (da) 1,2,5-oxadiazoler som inhibitorer af indolamin-2,3-dioxygenase
DK3003038T3 (da) 2h-1,2,3-triazolderivater som inhibitorer af fibrose
DK2981535T3 (da) Urinstofderivater, der er anvendelige som kinaseinhibitorer
DK2571963T3 (da) Sammensætninger, der tilvejebringer renseegenskab
DK3251678T3 (da) Benzoxaborolderivater til behandling af bakterieinfektioner
BR112013019327A2 (pt) composto, e, composição.
DK2658851T3 (da) Heterocykliske forbindelser, som er egnede til behandling af dyslipidæmi
CL2015000855A1 (es) Composicion de compuesto para juntas de tipo secado, bajo en agua.
DK2797581T3 (da) Formuleringer af (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methansulfonylethyl]-4-acetylaminoisoindolin-1,3-dion
DK3544981T3 (da) Benzodiazoliumforbindelser som enac-inhibitorer
DK3494993T3 (da) Ny anvendelse af maltotriosyl-transferase
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
MA41803A (fr) Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан